



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	128.35
Trade Time:	11:51 AM ET Aug 18, 2017
Change:	0.77 (0.604%)
Day Range	127.27 - 128.61
52-Week Range	96.93 - 139.00
Volume	1,312,682

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID[®], VIDAZA[®], THALOMID[®], POMALYST[®]/IMNOVID[®], ABRAXANE[®], OTEZLA[®], ISTODAX[®] and IDHIFA[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 1, 2017*
[FDA Grants Approval of IDHIFA[®] the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation](#)
- Jul 28, 2017*
[Celgene Corporation to Webcast at Upcoming Investor Conference](#)
- Jul 27, 2017*
[Celgene Reports Second Quarter 2017 Operating and Financial Results](#)
- Jul 25, 2017*
[Celgene Corporation Announces Settlement of Civil Litigation](#)
- Jul 5, 2017*
[Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers](#)

Financials [\[View all \]](#)

- Feb 10, 2017*
[Annual Report \(10-K\)](#)
- Apr 27, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Jul 27, 2017*
[Quarterly Report \(10-Q\)](#)
- Apr 27, 2017*
[Quarterly Report \(10-Q\)](#)
- Oct 27, 2016*
[Quarterly Report \(10-Q\)](#)